We conducted a prospective, long-term audit of lamotrigine and topiramate as add-on treatment for refractory epilepsy. A total of 55 patients participated in the study. Five years after starting the drug 7/20 patients remained on lamotrigine and 13/35 on topiramate. The patients still on the study drugs showed an improvement in seizure frequency, with 5/7 patients being seizure free on lamotrigine and 4/13 on topiramate. Furthermore, we assessed quality of life using the quality of life assessment schedule and found a significant improvement for the patients still on the study drugs. These data suggest that about one third of the patients on lamotrigine or topiramate as add-on therapy stay on the drug in the long term. These patients are likely to benefit with respect to objective and subjective outcome measures.
INTRODUCTION
Most patients with epilepsy are well controlled on monotherapy with one of the standard anti-epileptic drugs (AEDs). However, for about one third of patients with refractory epilepsy polytherapy is considered. This usually involves add-on therapy with one of the more recently introduced AEDs, such as lamotrigine, topiramate, gabapentin and vigabatrin. The efficacy and tolerability of these drugs have been demonstrated in controlled trials 1 . However, audits assessing the longevity of treatment with these agents have reported a high rate of patients stopping the new drug after the initial trial period 2 . There is preliminary evidence that lamotrigine and topiramate might have the lowest drop-out rates of the new AEDs 3, 4 .
In recent years, much attention has been given to the assessment of health-related quality of life (HRQL), often abbreviated to quality of life (QOL), and this is now acknowledged to be an important outcome measure in the evaluation of health care interventions. The history, development, and current status of measures to assess QOL(HRQL) in epilepsy have been comprehensively reviewed [5] [6] [7] . It is well documented that the occurrence of seizures and stigma of epilepsy lead to a variety of physical, psychological and social problems which have an impact on many areas such as self-esteem, work, career prospects, family, leisure, (in)ability to drive and relationships 7 . Although QOL has been assessed in clinical trials of antiepileptic drug therapy 8 , to our knowledge this issue has not been addressed by prospective audits beyond the initial trial period. The impact of medication on physical, psychological and social wellbeing is known, however, to play a role in patients' satisfaction and compliance with drug treatment 7 .
Our group has previously investigated patients on either lamotrigine or topiramate as add-on therapy over a 6 month period 9 . The investigators found that over half of patients were still on the drug (61-65%), but found a low level of patient satisfaction, when subjective criteria were included. In the present audit these patients were followed up 5 years after starting lamotrigine or topiramate as add-on therapy. In this study, in addition to measures relating to efficacy and tolerability of treatment, we assessed QOL at 5 year follow up.
Taking into account the low level of patient satisfaction after 6 months, we were expecting only a minority of the patients to be still on the study drugs. Regarding QOL we hypothesized a sustained improvement in the patients still on the study drug, while the patients not on the drug were likely to represent a heterogeneous group in terms of treatment and QOL.
METHODS

Subjects
Patients who had participated in the previous study were contacted by telephone. Of the patients started on topiramate 35/47 (74%) participated in the present study, two were cognitively unable to complete the interview, one declined to participate and nine were lost to follow-up. Of the patients started on lamotrigine 20/26 (77%) completed the interview, while six were lost to follow-up. All subjects were outpatients in a tertiary referral center.
Outcome measures
Seizure control
The national hospital seizure severity scale (NHS3) was used to assess seizure frequency and severity over the preceding three months 10 . It contains seven seizure-related factors and generates a score from 1 to 27. Seizure-related factors are presence of generalized convulsions, falls and injuries occurring during the seizure, incontinence, loss of consciousness, recovery time and disruptive automatisms.
Drug-related data
The patients current drug regimen was noted. Adverse events (requiring urgent medical treatment) and side effects (as perceived by the patient) were recorded. Adverse events were subjectively measured, i.e. data on adverse events were elicited directly from the patient and not from hospital or other notes.
Quality of Life (QOL)
QOL was measured by the quality of life assessment schedule (QOLAS), a generic, patient-driven semistructured QOL assessment, based on the personal construct theory and repertory grid technique 11, 12 . The QOLAS was chosen because it was previously demonstrated to be more sensitive to change in patients with epilepsy than some other QOL measures (generic and disease-specific) 12 . The QOLAS is a semi-structured interview which assesses ten areas of HRQL in five domains (physical, psychological, social, work/economic and cognitive functioning). The QOLAS has been used to assess the QOL of people with a number of neurological disorders, including epilepsy 12 , dementia 13 and Tourette syndrome 14 . During the QOLAS interview the patient is invited to select two 'constructs,' i.e. two items of importance to them, in each of the five domains. The scores can be presented as a profile and also as a global score, from 0 to 50, with higher scores indicating a worse HRQL. In this study the constructs elicited from each patient during the original base-line interview were used, i.e. at follow-up, the patient was invited to re-score each item. See Table 1 for a typical scoring example from the present study. The full QOLAS interview, which was used in the base-line research is conducted as follows:
(1) Introduction and rapport-building.
(2) The respondent is invited to recount what is important for his/her QOL and ways in which their current health condition is affecting their QOL. Key constructs are extracted from this narrative. Prompting is sometimes required.
(3) In total, ten 'constructs' are elicited, two for each of the following domains of QOL: physical, psychological, social, daily activities and cognitive functioning (or well-being).
(4) The patient is asked to rate how much of a problem each of these is now on a 0-5 scale, where 0 = no problem; 1 = very slight problem; 2 = mild problem; 3 = moderate problem; 4 = big problem and 5 = it could not be worse.
(5) The patient is asked to rate how much of a problem they would 'like' each of these to be ideally on a 0-5 scale as above.
(6) At follow-up interview, the respondent's individual constructs are read out to them and they The upper part of the table shows the number of patients who are still on the new AED (on LTG/TPM) and those off the new AED but treated with other medication (off LTG/TPM). Additionally, those who underwent either surgery (surgery) or implantation of a VNS are included. The lower part shows the number of patients in each subgroup, who are either seizure free or had at least a 50% reduction in seizure frequency of the most severe seizure type as assessed by the NHS3.
are invited to re-rate each on the 0-5 scale for how much of a problem there is with each 'now'.
Statistical analysis
In order to assess changes in QOL we performed repeated-measures ANOVA with overall QOLAS score as dependent measure. Between subject factor was medication (still on medication/off medication), within subject factor timepoint (time started on drug/present). Table 2 shows the number of patients still taking the original drug. Of the patients started on lamotrigine 7/20 (35%) were still taking the drug, compared to 13/35 (37%) in the topiramate group. A minority of patients underwent surgery or, in the topiramate group, implantation of a vagal nerve stimulator (VNS). Of the postsurgical patients one was still on lamotrigine, all the other patients with nonmedical treatment were taken off the drug under study. In the lamotrigine group, patients discontinued the drug because of sideeffects (4/12), lack of effect (3/12), a combination of both (3/12) or other reasons (2/12). In the topiramate group, patients discontinued the drug because of sideeffects (6/22), lack of effect (3/22), a combination of both (8/22) or other reasons. Table 2 also shows efficacy of treatment as reflected by two outcome criteria: (i) no seizures for at least 3 months or (ii) 50% reduction in frequency of the most severe seizure type as assessed by the NHS3. Of the seven patients still on lamotrigine five were seizure free for 3 months and all had at least 50% reduction in seizure frequency. Of the 13 patients still on topiramate four were seizure free and 10 had at least a 50% frequency reduction. Side-effects were noticed by 2/7 patients still on lamotrigine and 5/13 on topiramate. Two patients on lamotrigine reported blurred vision and mild dizziness. Three patients on topiramate complained about excessive daytime sleepiness and two about emotional instability. No adverse events were reported.
RESULTS
Medication and seizure frequency
Quality of life-qualitative data
The QOL issues most frequently mentioned by this group of patients are shown in Table 3 . Quality of life-statistical analysis Figure 1 shows the overall QOLAS scores for the patients started on lamotrigine. Repeated measures ANOVA showed a highly significant group (on LTG/off LTG) × timepoint (time drug started/present) interaction (P < 0.01). Patients still on the drug showed an improvement in their QOLAS score from 33.1 ± 7.6 to 12.7 ± 10.9. Patients off the drug did not show a significant change in QOLAS score (34.0±7.7 to 32.9 ± 8.2). The small number of patients who underwent surgery did not allow statistical comparison, but their data suggest an improvement in QOL.
Relationship between QOL and seizure frequency
In order to examine the relationship between QOL and seizure frequency, we conducted an exploratory correlation analysis. We found a significant correlation between QOLAS score and frequency of the most severe seizure type for the lamotrigine (r = 0.7, P < 0.01) as well as for the topiramate group (r = 0.39, P < 0.05).
DISCUSSION
In this study we have carried out a prospective audit of patients with refractory epilepsy treated with either lamotrigine or topiramate as add-on therapy. This study was not controlled and is limited by a relatively small sample size. However, it presents data on the actual clinical experience with two new antiepileptic agents and more importantly, it includes quality of life as an outcome measure.
In both medication groups about one third of the patients remained on the newly introduced drug after 5 years, which was a higher proportion than we expected. Walker et al. have reported that only 14% of the patients were still on lamotrigine after 6-8 years 2 . Similarly, Lhatoo et al. estimated by using Cox regression analysis that less than one fourth of patients with partial epilepsy are likely to continue on one of the new AEDs after 5 years 3 . However, in the Collins et al. study after 50 months 60% were still on lamotrigine and 50% still on TPM 4 . The differences between studies can partially be explained by the different time periods studied, but more important are probably differences in the patient population.
Treatment success was indicated by 50% reduction in seizure frequency in all patients still on lamotrigine and 10 out of 13 patients in the topiramate group. This suggests a substantial benefit in objective outcome measures for those patients still on the drug after 5 years. To our knowledge no study has previously reported seizure frequency data for lamotrigine or topiramate after this time period. Caution is necessary when directly comparing the drugs, because the two groups were not matched for demographic and epilepsy related variables.
Our hypothesis that the patients remaining on the studied drugs would experience an improvement in QOL was supported by the QOL data. Patients still on lamotrigine or topiramate showed an improvement in QOL. This was reflected by significantly lower QOLAS scores at 5-year follow up as compared to baseline data. Patients who came off their original drug and were treated with a different drug regimen, showed little overall change in QOL. We assessed QOL using a semi-structured, patient-driven technique. The QOLAS has been previously shown to be sensitive to change in QOL and in one study was shown to be more sensitive to change than the other QOL measures used 12 . When measuring quality of life a change of greater than 10% is generally thought to represent clinical as opposed to merely statistical significance 15 . Using this criterion, it can be argued that the substantial decrease of QOLAS scores in our study shows a clinically significant improvement in QOL, which reflects the patients' own views about what is relevant to their QOL and their perception of their current status.
The wide variety of factors influencing QOL is reflected by the diverse issues mentioned by our patients in the QOLAS interview. Important areas were seizure-related physical impairment, restricted social life, inability to work and cognitive problems, specifically memory. Our correlational analysis showed that there is a direct relationship between seizure control and QOL. However, the size of the correlation and the variety of topics mentioned by the patients suggests that there are other factors affecting QOL. It would be interesting to measure these factors such as reported memory deficits objectively in order to quantify their impact on QOL.
The relationship between seizure control, sideeffects, adverse events QOL and compliance is complex. Many patients are non-or partially compliant yet variables such as intelligence, socioeconomic level, personality, age and education have not correlated well with electronically monitored compliance (Cramer, 1996) 7 . The results of the present study suggest that patients take a number of factors into account when deciding whether or not to continue their medication. Of most importance was the balance of side-effects and seizure frequency. In addition, patients reported that their decisions were influenced by recent lifeevents and a minority of patients stopped the drug for reasons not related to their epilepsy at all. In this respect, the interpretation of our data has to be careful because the reasons for stopping the drug were elicited retrospectively and we had no data regarding QOL at the time the decision was actually made. However, this issue is of major clinical relevance and will be addressed in further research.
CONCLUSIONS
These long-term follow-up data on the outcome of treatment with lamotrigine or topiramate suggest that a substantial minority of about one third of the patients are likely to stay on these agents in the long-term. Furthermore, these patients show an improvement in objective as well as subjective outcome measures as indexed by seizure frequency and QOLAS score. However, it remains an open issue how this patient subgroup can be identified before initiating add-on therapy with one of the agents under study.
